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Abstract
Objective: Herpes simplex virus (HSV) reactivation has been identified as a possible risk factor for Alzheimer’s disease (AD)
and plasma amyloid-beta (Ab) levels might be considered as possible biomarkers of the risk of AD. The aim of our study was
to investigate the association between anti-HSV antibodies and plasma Ab levels.
Methods: The study sample consisted of 1222 subjects (73.9 y in mean) from the Three-City cohort. IgM and IgG anti-HSV
antibodies were quantified using an ELISA kit, and plasma levels of Ab1–40 and Ab1–42 were measured using an xMAP-based
assay technology. Cross-sectional analyses of the associations between anti-HSV antibodies and plasma Ab levels were
performed by multi-linear regression.
Results: After adjustment for study center, age, sex, education, and apolipoprotein E-e4 polymorphism, plasma Ab1–42 and
Ab1–40 levels were specifically inversely associated with anti-HSV IgM levels (b=220.7, P=0.001 and b=292.4, P=0.007,
respectively). In a sub-sample with information on CLU- and CR1-linked SNPs genotyping (n=754), additional adjustment for
CR1 or CLU markers did not modify these associations (adjustment for CR1 rs6656401, b=225.6, P=0.002 for Ab1–42 and
b=2132.7, P=0.002 for Ab1–40; adjustment for CLU rs2279590, b=225.6, P=0.002 for Ab1–42 and b=2134.8, P=0.002 for
Ab1–40). No association between the plasma Ab1–42-to-Ab1–40 ratio and anti-HSV IgM or IgG were evidenced.
Conclusion: High anti-HSV IgM levels, markers of HSV reactivation, are associated with lower plasma Ab1–40 and Ab1–42
levels, which suggest a possible involvement of the virus in the alterations of the APP processing and potentially in the
pathogenesis of AD in human.
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Introduction
Previous researches have suggested that Herpes Simplex Virus
(HSV), notably type 1 (HSV-1), may constitute a risk factor of
Alzheimer’s disease (AD) [1,2,3,4]. We recently assessed the
association between seropositivity to HSV and risk of AD in the
PAQUID study and found that elderly subjects who were IgM-
positive were more likely to develop dementia within the next 7
years while no association was found among IgG-positive subjects
[5]. These results suggest that a recent reactivation of HSV,
characterized by the specific association with anti-HSV IgM
antibodies, may be involved in the long-term neuropathological
processes leading to dementia [5]. The identification of
intermediary biomarkers within the amyloid cascade would
considerably strengthen the case for the causal relationship
suggested by epidemiological evidence. The relevance of plasma
biomarkers of AD, notably of the amyloid b fragment (Ab1–40 and
Ab1–42), has recently been investigated in humans, producing some
conflicting results [6]. Indeed, in some studies, AD subjects
exhibited higher Ab1–40 or Ab1–42 plasma levels compared to
controls while others studies have reported opposing data [6]. We
have previously reported that an increased Ab1–42-to-Ab1–40
plasma ratio was strongly negatively associated with the risk of
dementia 2 years later in the Three-City population-based cohort,
suggesting that changes in plasma Ab1–40 and Ab1–42 levels might
be considered an indicator of short-term risk of dementia [7]. A
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29480meta-analysis of plasma Ab levels in AD suggested that in
longitudinal studies these parameters might be predictors of higher
rates of progression to AD, and should be further explored as
potential biomarkers [8].
In the relationship linking HSV to AD, our hypothesis is that a
specific association between anti-HSV IgM, and not IgG,
antibodies and plasma Ab levels might occur in the pre-clinical
phase of the dementia syndrome. The present study examined
whether anti-HSV antibodies were associated with plasma Ab1–40,
Ab1–42 and Ab1–42-to-Ab1–40 ratio in a sample of older community
dwellers from the Three-City study, and whether this association
may be modulated by genetic risk factors for AD; Apolipoprotein
E-allele e4 (ApoE4), CR1 and CLU, which have also been involved
in the HSV life cycle [2,9].
Results
The main study sample consisted of 1222 individuals, aged
73.9 y on average (range 65.0–94.1) and the secondary study
sample, with CLU- and CR1- linked SNPs genotyping determina-
tion, consisted of 754 subjects, aged 74.0 y on average (range
65.0–92.0). Their main characteristics are described in Table 1.
In the main study sample, only the crude correlation between
anti-HSV IgM levels and plasma Ab1–40 and Ab1–42 levels were
statistically significant (r=20.074, P=0.009 and r=20.087,
P=0.002 respectively). Moreover, mean plasma Ab1–40 and
Ab1–42 levels significantly differed according to the quartiles of
anti-HSV IgM distribution in crude analyses (Table 2). The
lowest mean plasma Ab1–40 and Ab1–42 levels were observed in the
highest quartile of anti-HSV IgM. As a consequence, the mean
Ab1–42-to-Ab1–40 ratio did not differ among quartiles of distribu-
tion of anti-HSV IgM. These results were virtually unchanged
when these analyses were performed in the secondary study
sample (n=754) (Table 3). In contrast, there was no significant
difference in means of plasma Ab1–40 and Ab1–42 and of the
Ab1–42-to-Ab1–40 ratio according to quartiles of anti-HSV IgG
distribution in the main study sample (Table 2) as in the
secondary study sample (Table 3).
Associations between plasma Ab1–40 and Ab1–42 levels and of
the Ab1–42-to-Ab1–40 ratio and anti-HSV IgM levels, considered as
a continuous or class variable, in the main study sample are shown
in Table 4. After adjustment for study center, age, sex and
education, plasma Ab1–40 and Ab1–42 levels were significantly
inversely associated with anti-HSV IgM (Table 4, model 1). The
strength of these associations remained almost unchanged after
additional adjustment for ApoE polymorphism (Table 4, model
1+ApoE4). When considering anti-HSV IgM levels as a class
variable, the highest quartile of IgM was associated with a level of
Ab1–42 decreased on average of 2.9 pg/mL and a level of Ab1–40
decreased of 11.6 pg/mL in fully adjusted models. No association
between the plasma Ab1–42-to-Ab1–40 ratio and anti-HSV IgM
levels was evidenced in multivariate linear regression analyses
(Table 4). Considering anti-HSV IgG levels either as a continuous
or a categorical variable, no association with plasma Ab1–40,
Ab1–42 or the Ab1–42-to-Ab1–40 ratio were evidenced (Table S1).
Finally, no significant statistical interaction with ApoE4 polymor-
phism was found in any model.
In a sensibility analysis, similar results were obtained when
subjects who developed incident dementia during the follow-up
were excluded (n=40) (Table S2).
Given the potential involvement of the complement C3b
protein, and so CR1, and of CLU in Ab clearance and pathogen
defence, associations between plasma Ab1–40,A b1–42 levels and
Ab1–42-to-Ab1–40 ratio and anti-HSV IgM or IgG levels were
assessed in the secondary study sample where CR1- and CLU-
linked SNPs markers were available. In this sub-population
(n=754), results of inverse associations between plasma Ab1–40
and Ab1–42 and anti-HSV IgM levels remained almost unchanged
(Table 5, model 1). As previously observed in the main study
sample, no association between the Ab1–42-to-Ab1–40 ratio and
IgM antibody levels was found. Furthermore, no association
between plasma Ab1–40,A b1–42 and the Ab1–42-to-Ab1–40 ratio
and anti-HSV IgG levels were observed (Table S1). When
controlling for rs6656401 (Table 5, model 1+CR1)o r
rs3818361 (Table S3, model 1) at the CR1 locus, or for
rs2279590 (Table 5, model 1+CR1) or rs9331888 and
rs11136000 (Table S3, model 1 + CR1 or CLU) at the CLU
locus, results of inverse associations between plasma Ab1–40 and
Ab1–42 and anti-HSV IgM were virtually unchanged. In fully
adjusted models for ApoE4, CR1- and CLU- linked SNP, this
inverse association remained significant (Table 5). No significant
statistical interaction with any CR1-o rCLU- linked SNP was
found in any model.
Discussion
This population-based cohort study is the first to report that
higher plasma IgM antibodies to HSV levels were significantly
associated with lower plasma Ab1–40 and Ab1–42 levels. No
association between anti-HSV IgG antibodies and plasma Aß
Table 1. Main characteristics of the main study sample and
the secondary study sample.
Main study
sample
Secondary
study sample
(n=1222) (n=754)
Age, y, mean (SD) 73.9 (5.3) 74.0 (5.4)
Women, % 60.4 61.7
Low educational level,* % 60.6 59.1
ApoE e4-allele frequency, % 20.4 21.2
Ab1–42, pg/mL, mean (SD) 38.9 (12.3) 39.1 (12.1)
Ab1–40, pg/mL, mean (SD) 235.6 (66.2) 234.5 (63.8)
Ab1–42/Ab1–40 ratio, mean (SD) 0.17 (0.05) 0.17 (0.05)
IgG antibodies to HSV,
IU/mL, mean (SD)
12.61 (7.03) 12.46 (7.11)
IgM antibodies to HSV,
IU/mL, mean (SD)
0.053 (0.055) 0.052 (0.053)
CR1 rs6656401
{ (%) ND 34.0
CR1 rs3818361
{ (%) ND 33.2
CLU rs9331888
{ (%) ND 48.4
CLU rs2279590
N (%) ND 66.7
CLU rs11136000
N (%) ND 64.7
Abbreviations: ApoE, apolipoprotein E; HSV, herpes simplex virus; Ab, amyloid-
beta; ND, not determined.
*Low educational level=short secondary school level or less.
{These genotyped markers of CR1 were considered dichotomously: at least one
adenine (GA or AA), the minor allele, vs. no adenine purine base (GG) in
haplotypes.
{The genotyped marker of CLU rs9331888 was considered dichotomously: at
least one guanine (CG or GG), the minor allele, vs. no guanine purine base (CC)
in haplotypes.
NThese genotyped markers of CLU were considered dichotomously: at least one
thymine (TC or TT), the minor allele, vs. no thymine pyrimidine base (CC) in
haplotypes. Eleven data for CLU rs11136000 were missing.
doi:10.1371/journal.pone.0029480.t001
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polymorphism, CR1 and CLU markers.
Beside previous knowledge [5][7], our hypothesis suggested that
an association between anti-HSV IgM and plasma Aß levels would
exist during the long prodromal phase of dementia. Although
HSV was present in both normal and AD brains, several lines of
evidence have already suggested potential scenarios by which
HSV may participate in the complex pathogenesis of dementia
[1,3]. The brain areas which are predominantly targeted by HSV
infectious agents in herpetic encephalitis include frontal cortex,
temporal cortex and hippocampus, and are also those predomi-
nantly affected in AD [4]. Second, HSV-1 is ubiquitous and could
reside latently in the central nervous system (CNS) or could easily
enter the CNS because of a decline in the immune system with
advancing age [10]. A hypothesis has suggested that periodic mild
reactivation of the latent virus in the brain, because of age-related
immunosuppression or stress, for the most part without evident
clinical symptoms, may lead to increased cell damage, and
indirectly, via inflammatory processes, increased susceptibility for
AD [11]. This hypothesis has been in part confirmed in the
PAQUID study [5] and altogether, these results were in favour of
a long-term effect of recurrent reactivations of HSV leading to
progressive brain damage, and several years later, to dementia.
The replication of the PAQUID study analyses was not our main
objective since participants of the case-cohort involved in the
present analyses were followed-up only for 4 years.
The amyloid cascade hypothesis suggests that aberrant
metabolism of the amyloid precursor protein (APP) and subse-
Table 2. Mean plasma amyloid-b levels by quartiles of distribution of IgM or IgG antibodies to herpes simplex virus in the main
study sample (n=1222).
IgM antibodies to herpes simplex virus (IU/mL)
1
st quartile 2
nd quartile 3
rd quartile 4
th quartile
#0.018 [0.018–0.034] [0.034–0.067] .0.067
Mean (SD) P
Ab1–42, pg/mL 40.3 (12.7) 39.3 (13.2) 39.1 (12.2) 36.8 (10.7) 0.0036
Ab1–40, pg/mL 241.4 (65.6) 243.2 (80.0) 230.3 (58.0) 226.9 (56.5) 0.0035
Ab1–42-to-Ab1–40 ratio 0.17 (0.04) 0.17 (0.05) 0.17 (0.05) 0.17 (0.06) 0.3566
IgG antibodies to Herpes Simplex Virus (IU/mL)
1
st quartile 2
nd quartile 3
rd quartile 4
th quartile
#7.2 ]7.2–15.0] ]15.0–18.0] .18.0
Mean (SD) P
Ab1–42, pg/mL 38.29 (13.17) 40.04 (11.14) 38.56 (12.32) 38.42 (12.82) 0.2403
Ab1–40, pg/mL 232.72 (66.61) 235.52 (58.65) 237.28 (69.11) 237.11 (71.91) 0.8195
Ab1–42-to-Ab1–40 ratio 0.17 (0.04) 0.18 (0.07) 0.17 (0.05) 0.17 (0.05) 0.0907
doi:10.1371/journal.pone.0029480.t002
Table 3. Mean plasma amyloid-b levels by quartiles of distribution of IgM or IgG antibodies to herpes simplex virus in the
secondary study sample (n=754).
IgM antibodies to herpes simplex virus (IU/mL)
1
st quartile 2
nd quartile 3
rd quartile 4
th quartile
#0.018 [0.018–0.033] [0.033–0.066] .0.066
Mean (SD) P
Ab1–42, pg/mL 40.4 (11.7) 39.3 (13.0) 40.1 (13.0) 36.6 (10.3) 0.0097
Ab1–40, pg/mL 242.5 (65.5) 240.4 (71.5) 229.8 (61.2) 225.0 (54.5) 0.0203
Ab1–42/Ab1–40 ratio 0.17 (0.04) 0.17 (0.06) 0.18 (0.05) 0.17 (0.06) 0.2401
IgG antibodies to herpes simplex virus (IU/mL)
1
st quartile 2
nd quartile 3
rd quartile 4
th quartile
#6.90 [6.90–15.00] [15.00–18.00] .18.00
Mean (SD) P
Ab1–42, pg/mL 39.0 (12.7) 40.1 (11.4) 38.0 (10.8) 39.2 (14.4) 0.3655
Ab1–40, pg/mL 232.9 (66.1) 232.9 (56.7) 233.7 (54.4) 240.9 (83.5) 0.6575
Ab1–42/Ab1–40 ratio 0.17 (0.04) 0.18 (0.07) 0.17 (0.05) 0.17 (0.05) 0.2446
doi:10.1371/journal.pone.0029480.t003
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determinant of AD [12]. Repercussions of such brain alterations
to peripheral Aß levels are only partly understood [6]. It has been
suggested that plasma Aß levels gradually decreased over time with
the increased brain Aß deposition in human as well [13]. Recent
results of an increased PiB-PET uptake being associated with
lower plasma Aß levels in Mild Cognitive Impairment supported
the ‘‘sink hypothesis’’ that increased amyloid deposition in the
brain is accompanied by lower peripheral Aß levels in plasma [14].
In that case, low plasma Aß levels might be considered possible
short-term risk markers of dementia and could reflect prior
sequestration of Aß in the brain [7,13,14,15]. The finding by Yaffe
et al. fitted comfortably within this hypothesis since plasma Ab1–42
levels and the Ab1–42-to-Ab1–40 ratio correlated with cognitive
decline [16]. Because of the fluctuation of plasma Aß levels during
the presymptomatic dementia period, the accurate dynamic
process of plasma Aß levels is not well known so far.
Interestingly, several studies have also linked HSV to Aß [11].
Indeed, a segment of Aß is highly homologous to a glycoprotein
encoded by the virus, and an association between HSV-1 and APP
during axonal transport of the virus may lead to alter the APP
processing [11,17,18]. For instance, Cheng et al. have illustrated
the possible role of HSV-1 in the APP dynamic, by showing that
HSV-1-infected cells displayed abnormal APP distribution, and
that APP and HSV-1 capsids co-localized and travelled together
within cells [19]. Secondly, a striking localisation of HSV-1 DNA
within amyloid plaques in human AD brains has also been
reported [20]. Third, infection with HSV-1 increases the enzymes
responsible for Ab formation in mice brains and leads to Ab
accumulation [21,22,23]. In a neuronal cell culture model, HSV
increases the formation of Ab oligomers [24] while in HSV-1-
infected cells, antiviral agents reduced the accumulation of Ab and
of phospho-Tau [25]. On the other hand, Ab fibrils have been
shown to facilitate the entry of several viruses, including HSV-1
[26], a mechanism considered as an initially protective response
against the viral infection [4]. Anyway, an anti-infectious activity
has been attributed to Ab [27] suggesting that brain cells might
produce Ab in an attempt to combat infections.
Altogether, these results suggest that infection earlier in life with
HSV in the peripheral nervous system, with subsequent infection
in CNS, leads to activation of the immune system, altering APP
metabolism. Recurrent periodic mild reactivation of latent HSV in
CNS, as associated with anti-HSV IgM levels, may lead to
gradually increased production of Ab. The continuous Ab
accumulation in brains cells may eventually result in later changes
in periphery as assessed by instability of plasma Ab levels during
the long prodromal phase of dementia and afterwards by
decreased plasma Ab levels in the very last years before the
diagnosis [7,15]. Toxicity-related Ab over-production, concomi-
tant with multiple HSV reactivations, thus in effect, a persistent
infection, might be conducive to progressive brain injury, with
increasing cognitive dysfunction, leading to dementia several years
later [5]. If this hypothesis is true, the first HSV infection of brain
may constitute a trigger for the amyloid cascade. The reactivation
of the virus may exacerbate these brain alterations during the long
time course preceding the clinical diagnosis of dementia. This is
confirmed by unchanged results obtained by sensitivity analyses
where subjects who developed dementia in the short-term (in the
four subsequent years) were excluded in the present study. Finally,
the lack of association between anti-HSV IgG antibodies, markers
of past infection, and plasma Aß levels in the present study also
reinforced the present hypothesis.
Inflammatory response of immune system against many viral
infections, including HSV-1, is a possible indirect way by which
Table 4. Associations between plasma amyloid-ß levels and
IgM antibodies to herpes simplex virus in the main study
sample (n=1222).
IgM antibodies to herpes simplex virus
Per one
additional
unit
4
th vs. 1
st-2
nd-
3
rd quartiles
b (SE) P b (SE) P
Ab1–42
Model 1 220.9 (6.4) 0.001 23.0 (0.8) 0.0003
Model 1+ApoE4* 220.7 (6.4) 0.001 22.9 (0.8) 0.0003
Ab1–40
Model 1 293.0 (34.4) 0.007 211.7 (4.4) 0.007
Model 1+ApoE4* 292.4 (34.4) 0.007 211.6 (4.4) 0.008
Ab1–42/Ab1–40 ratio
Model 1 20.0007 (0.03) 0.98 20.002 (0.003) 0.56
Model 1+ApoE4* 0.0002 (0.03) 0.99 20.002 (0.003) 0.57
Model 1 adjusted for study center, age, gender and educational level.
*Model 1 plus additional adjustment for apolipoprotein E-e4 polymorphism.
doi:10.1371/journal.pone.0029480.t004
Table 5. Associations between plasma amyloid-b levels and
IgM antibodies to herpes simplex virus in the secondary study
sample with CR1- and CLU-linked SNPs available data
(n=754).
IgM antibodies to herpes simplex virus
Per one
additional
unit
4
th vs. 1
st-
2
nd-3
rd
quartiles
b (SE) P b (SE) P
Ab1–42
Model 1 225.7 (8.3) 0.002 23.5 (1.0) 0.0007
Model 1+CR1* 225.6 (8.4) 0.002 23.5 (1.0) 0.0008
Model 1+CLU
{ 225.6 (8.3) 0.002 23.5 (1.0) 0.0007
Model 1+CR1+CLU
{ 225.5 (8.3) 0.002 23.5 (1.0) 0.0007
Ab1–40
Model 1 2134.7 (43.6) 0.002 212.0 (5.4) 0.03
Model 1+CR1* 2132.7 (43.6) 0.002 211.6 (5.4) 0.03
Model 1+CLU
{ 2134.8 (43.6) 0.002 211.9 (5.4) 0.03
Model 1+CR1+CLU
{ 2132.8 (43.7) 0.002 211.6 (5.4) 0.03
Ab1–42/Ab1–40 ratio
Model 1 0.02 (0.04) 0.61 20.004 (0.005) 0.43
Model 1+CR1* 0.02 (0.04) 0.63 20.004 (0.005) 0.41
Model 1+CLU
{ 0.02 (0.04) 0.60 20.004 (0.004) 0.42
Model 1+CR1+CLU
{ 0.02 (0.04) 0.62 20.004 (0.004) 0.40
Model 1 adjusted for study center, age, gender, educational level and
apolipoprotein E-e4 polymorphism.
*Model 1 plus additional adjustment for CR1 marker at rs6656401.
{Model 1 plus additional adjustment for CLU marker at rs2279590.
{Model 1 plus additional adjustment for CR1 marker at rs6656401 and CLU
marker at rs2279590.
doi:10.1371/journal.pone.0029480.t005
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neuroinflammation, due to HSV-1 infection and/or consequently
to neuropathological processes, may contribute to increase
oxidative stress, to which the CNS is highly sensitive [28].
Oxidative damage is commonly observed in AD, even in the early
stages of the disease [29], and viral infection, such as HSV, also
leads to over-production of reactive oxygen and nitrogen species
[11,30]. Finally, the efficacy of the autophagy, considered as usual
cellular defences mechanism involved in AD, would be reduced by
HSV-1 for its own survival [23,31,32,33,34].
Complex interactions between HSV life cycle and major
susceptibility AD gene products, including CR1 and CLU [9], have
also recently been suggested [2,11]. However, our results are not in
favour of different associations between anti-HSV IgM and plasma
Ab among carriers of the CR1 or CLU predisposing genetic factors.
Associationsbetweenanti-HSVIgMandplasmaAb levelswerealso
not modulated by ApoE4 polymorphism in the present study,
consistent with at least one previous observation that ApoE4 does
not modify the association between HSV seropositivity and risk of
AD [5], although other studies have suggested that it might
[35,36,37]. Nevertheless, all potential genes/infection interactions
have not yet been fully studied and require further investigation [2].
Our results should be interpreted with caution due to some
limitations. First, since our study was cross-sectional, we could not
determine whether the low observed plasma Ab levels were the
result of reactivation of HSV or whether plasma Ab levels pre-
dated elevated anti-HSV IgM levels. Indeed, an alternative
explanation is that the possible accumulation of Ab in brain cells,
with subsequentlow plasmaAb levels,might be the first step of AD-
related neuropathological processes, and might furthermore be
characteristic of favourable conditions for latent HSV reactivation
in the CNS. Second, plasma Ab does not only reflect brain Ab
turnover and metabolism but also that derived from peripheral
tissues [6,38]. The relevance of repeated measurements of plasma
Ab and anti-HSV IgM levels to assess the timeline of the events
during the prodromal period of the dementia process would
reinforce our main hypothesis, although it was not obtainable.
Moreover, measurement of plasma Ab is subject to many potential
confounds that induce biological variations and we can not exclude
that these variations might in part increased our chance to evidence
associations [39]. Cerebrospinal fluid (CSF) is thought to more
closely reflect what is happening in the brain. CSF Ab1–42 levels
have been associated with current AD or shown to be predictive of
future dementia in patients with Mild Cognitive Impairment [6].
Therefore, the replication of the present analyses with CSF
biomarkers would be of great interest. No such samples were
available in the 3C cohort, leading us to be unable to perform these
analyses. However, among groups with different cognitive abilities
in ADNI, the plasma Ab had a better correlation with Ab brain
deposits than CSF Ab values [40]. Third, the sub-type of HSV
(HSV-1 or HSV-2) was not determined in this study, although it is
most likely that participants were infected by HSV-1. Indeed,
HSV-1 infection is more frequent than HSV-2 and herpes simplex
encephalopathy caused by HSV-2 is very rare in adults [41].
Several strengths of this study must be underlined. As plasma
Ab concentration varies widely during the prodromal phase of
dementia [7], our large sample size increases the validity of the
observations. Moreover, this population-based study was conduct-
ed in the 3C cohort, which is independent sample of the previous
cohort (the PAQUID study) [5].
To conclude, we have shown that HSV reactivation, assessed by
increased anti-HSV IgM levels, is associated with lower plasma
Ab1–40 and Ab1–42 levels, lending further support to the hypothesis
that HSV may be implicated in the dynamic of the APP processing
and potentially in the pathogenesis of AD in human. Further
research is needed to establish the direction of causality and to
explain the underlying mechanisms.
Methods
Participants
The data come from the Three-City (3C) study, a prospective
cohort study of vascular risk factors of dementia whose
methodology is described in detail elsewhere [42]. The protocol
of the 3C study was approved by the Consultative Committee for
the Protection of Persons participating in Biomedical Research of
the Kremlin-Bice ˆtre University Hospital (Paris). A sample of 9294
community dwellers aged 65 and over was selected in 1999–2000
from the electoral rolls of three French cities: Bordeaux (n=2104),
Dijon (n=4931) and Montpellier (n=2259). All participants
signed a written consent and all clinical investigations have been
conducted according to the principles expressed in the ‘‘Declara-
tion of Helsinki’’.
At the baseline clinical examination, data were assessed using
standardised questionnaires and a blood sample was obtained.
Participants were reexamined two (2001–2003; n=8072) and four
(2003–2005; n=7148) years after the baseline examination.
During this follow-up period, incident dementia were actively
screened, using a two step procedure following administration of
the battery of neuropsychological tests [42]. At each wave,
participants suspected of having dementia based on their present
neuropsychological performances or decline relative to a previous
examination were examined by a neurologist. An independent
committee of neurologists then reviewed all potential cases of
dementia and analysed in depth the medical history of each
participant to obtain a consensus on the diagnosis and etiology
according to the criteria of the Diagnostic and Statistical Manual of
Mental Disorders, fourth edition.
A case–cohort study was conducted at the end of 4 years of
follow-up for the investigation of non-standard risk markers for
dementia, stroke and coronary heart disease (Fig. 1). Among the
9294 subjects of the initial cohort, 880 were excluded because either
they had no blood sampling or they did not participate in any of the
follow-up examinations, leading to a remaining sample of 8414. For
the present work, the case–cohort study comprised a subcohort of
1254 subjects randomly selected in strata defined according to
center, age (5 years), and sex. Among them, twenty-nine subjects
were diagnosed as having prevalent dementia at baseline and were
thus excluded from the current analysis. Incident dementia was
diagnosed in 40 participants included in the subcohort. Participants
for whom at least one Aß plasma concentration (n=3) or IgM or
IgG antibodies to HSV quantification (n=0) was missing were
excluded. These selection steps allowed us to define a main study
sample of 1222 participants (Fig. 1).
Assessment of plasma amyloid-b concentration
Blood samples were all obtained early in the morning,
simultaneously to the baseline data collection. Blood was collected
in anticoagulant (EDTA) vacutainers and centrifuged at 1.000 g
for 10 minutes. Plasma samples were aliquoted and were frozen
immediately at 280uC.
The plasma Ab quantification was described in details
elsewhere [7]. Briefly, the baseline plasma Ab peptide assay was
performed using an INNO-BIA kit (Innogenetics, Ghent, Belgium)
based on a multiplex xMAP (Luminex, Austin, TX) technique.
Knowing the dynamic of plasma amyloid levels according to
matrix type and technical processing, we used the INNO-BIA kit
as one of the more reliable commercial amyloid ELISA kits [39].
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mined and the Ab1–42-to-Ab1–40 ratio was computed.
IgM and IgG antibodies to Herpes Simplex Virus
quantification
A high sensitive and specific ELISA diagnostic kit (Enzygnost
Anti HSV/IgM and IgG, Dade Behring, Marburg, Germany) was
used to quantify anti-HSV IgM antibodies (anti-HSV IgM) and
anti-HSV IgG antibodies (anti-HSV IgG) [5,43]. IgM and IgG
titres are expressed in international unit per milliliter (UI/mL).
Potential confounders
Socio-demographic information included age, sex, and educa-
tion. Apolipoprotein E (ApoE) genotyping was performed at the
Lille Genopole (France) and ApoE4 genotype was considered
dichotomously: presence of at least one e4 allele vs. no e4 allele
[44]. DNA of a subsample of participants of the 3C study,
transferred to the French Centre National de Genotypage for
genome wide assessment, gives us information on CLU- and CR1-
linked SNPs genotyping [9]. Among them, 754 subjects of the
case-control study, for whom markers of CR1-linked SNPs
(rs6656401 and rs3818361) and CLU-linked SNPs (rs9331888,
rs2279590 and rs11136000) have been determined, constituted the
secondary study sample for the present analysis (Fig. 1) [9].
Eleven data for CLU rs11136000 were missing.
Statistical analyses
All statistical analyses were performed with SAS Statistical
package (Version 9.1 SAS Institute). Demographic, biological and
genetic characteristics were described in the main study sample
(n=1222) and in the secondary study sample (n=754). In the
main study sample, the crude association between plasma Ab1–40,
Ab1–42 and the Ab1–42-to-Ab1–40 ratio and the anti-HSV IgM or
anti-HSV IgG levels were performed. Moreover, the quartiles of
distribution of anti-HSV IgM and anti-HSV IgG were defined and
mean plasma Ab1–40,A b1–42 and the Ab1–42-to-Ab1–40 ratio were
compared using analysis of variance (ANOVA) or Kruskal-Wallis
test when ANOVA hypotheses were not satisfied (accepted
significance at P,0.05). Cross-sectional analyses of the association
between plasma Ab1–40 and Ab1–42 levels and the Ab1–42-to-Ab1–40
ratio (entered into separate models as continuous variables) and
anti-HSV IgM or anti-HSV IgG were separately performed by
multivariate linear regression. Anti-HSV IgM or IgG levels have
been considered as continuous variable on the one hand (i.e.
analysis for one additional unit of IgM or IgG) and as dichotomous
variable on the other hand: the highest quartile of distribution of
anti-HSV IgM or IgG was compared with the clustered three other
quartiles, chosen as reference. These analyses were adjusted for
study center, age (continuous), sex, and education level in model 1
and additionally for ApoE genotype in model 2. Statistical
interactions between IgM or IgG levels and ApoE genotype were
tested. In a sensitivity analysis, subjects with incident dementia
(n=40) were excluded.
All these analyses were replicated in a sub-sample of 754
subjects with available data on genotyped markers of CR1 and
CLU (Fig. 1). Multivariate linear regression models of the
association between plasma Ab1–40,A b1–42 levels and the
Ab1–42-to-Ab1–40 ratio (entered into separate models as continuous
variables) and anti-HSV IgM or IgG were adjusted for study
center, age (continuous), sex, education level and ApoE genotype
in model 1. Additional adjustments for CR1 markers (rs6656401
Figure 1. Design of the case-control study, definition of the main study sample and of the secondary study sample. Abbreviations:
HSV, herpes simplex virus; Ab, Amyloid-beta; 3C, Three-City Study.
doi:10.1371/journal.pone.0029480.g001
Herpes Simplex Virus and Plasma Ab
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e29480on the one hand and rs3818361 on the other hand) and for CLU
markers (rs9331888, rs2279590 and rs11136000 in separated
models) were performed. Finally, additional models taken into
account the ApoE4 genotype, CR1 and CLU markers as
adjustment variables have been performed. Statistical interactions
between IgM or IgG levels and CR1-o rCLU- linked SNPs were
tested.
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